These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 17214827

  • 1. Time-dependent clearance of mycophenolic acid in renal transplant recipients.
    van Hest RM, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, Mathot RA.
    Br J Clin Pharmacol; 2007 Jun; 63(6):741-52. PubMed ID: 17214827
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, van Gelder T.
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction.
    Guillet BA, Simon NS, Purgus R, Botta C, Morange S, Berland Y, Pisano PS.
    Ther Drug Monit; 2010 Aug; 32(4):427-32. PubMed ID: 20592648
    [Abstract] [Full Text] [Related]

  • 5. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.
    Lamba M, Tafti B, Melcher M, Chan G, Krishnaswami S, Busque S.
    Ther Drug Monit; 2010 Dec; 32(6):778-81. PubMed ID: 20926996
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.
    van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA.
    Clin Pharmacokinet; 2009 Dec; 48(7):463-76. PubMed ID: 19691368
    [Abstract] [Full Text] [Related]

  • 11. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.
    de Winter BC, Monchaud C, Prémaud A, Pison C, Kessler R, Reynaud-Gaubert M, Dromer C, Stern M, Guillemain R, Knoop C, Estenne M, Marquet P, Rousseau A.
    Clin Pharmacokinet; 2012 Jan 01; 51(1):29-39. PubMed ID: 22054177
    [Abstract] [Full Text] [Related]

  • 12. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.
    Musuamba FT, Mourad M, Haufroid V, Demeyer M, Capron A, Delattre IK, Delaruelle F, Wallemacq P, Verbeeck RK.
    J Clin Pharmacol; 2012 Dec 01; 52(12):1833-43. PubMed ID: 22207766
    [Abstract] [Full Text] [Related]

  • 13. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S, Hishida A, Kagawa Y, Kawakami J.
    Ther Drug Monit; 2008 Dec 01; 30(6):656-61. PubMed ID: 18978521
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
    Transplant Proc; 2005 Mar 01; 37(2):864-6. PubMed ID: 15848558
    [Abstract] [Full Text] [Related]

  • 15. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients.
    Naesens M, Verbeke K, Vanrenterghem Y, Kuypers D.
    Br J Clin Pharmacol; 2007 May 01; 63(5):541-7. PubMed ID: 17094777
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y.
    Clin Pharmacol Ther; 2004 May 01; 75(5):434-47. PubMed ID: 15116056
    [Abstract] [Full Text] [Related]

  • 17. Significant Effects of Renal Function on Mycophenolic Acid Total Clearance in Pediatric Kidney Transplant Recipients with Population Pharmacokinetic Modeling.
    Rong Y, Wichart J, Hamiwka L, Kiang TKL.
    Clin Pharmacokinet; 2023 Sep 01; 62(9):1289-1303. PubMed ID: 37493886
    [Abstract] [Full Text] [Related]

  • 18. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.
    Prémaud A, Debord J, Rousseau A, Le Meur Y, Toupance O, Lebranchu Y, Hoizey G, Le Guellec C, Marquet P.
    Clin Pharmacokinet; 2005 Sep 01; 44(8):837-47. PubMed ID: 16029068
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.
    Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, McCune JS.
    J Clin Pharmacol; 2013 Apr 01; 53(4):393-402. PubMed ID: 23382105
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation.
    Staatz CE, Duffull SB, Kiberd B, Fraser AD, Tett SE.
    Eur J Clin Pharmacol; 2005 Aug 01; 61(7):507-16. PubMed ID: 16049701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.